To the editor [10]

New England Journal of Medicine

Volumn 357, Issue 12, 2007, Pages 1257-1258

  Dickstein, Gabriel ^a   Shechner, Carmela ^a   Nativ, Ofer ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

MITOTANE;

ADRENAL CORTEX CARCINOMA; ADVANCED CANCER; CANCER CONTROL; CANCER PATIENT; CANCER SIZE; CANCER STAGING; HUMAN; LETTER; METASTASIS; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT INDICATION;

EID: 34548823547     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Schteingart DE. Adjuvant mitotane therapy of adrenal cancer - use and controversy. N Engl J Med 2007;356:2415-8.
2. Dickstein G, Shechner C, Arad E, Best L-A, Nativ O. Is there a role for low doses of mitotane (o,p?-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 1998;83:3100-3.
3. Barzon L, Fallo F, Sonino N, Danielle O, Boscaro M. Comment - is there a role for low doses of mitotane (o,p′-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 1999;84:1488-9.